论文部分内容阅读
目的:对贝拉普利在高血压合并糖尿病患者中的治疗效果进行调查。方法:抽选78例高血压合并糖尿病患者,所有患者均为2014年10月-2016年月间入院治疗的人员,将所有患者随机分为观察组和对照组,每组39例,对照组患者采用常规方式进行治疗,观察组患者同时联合贝拉普利进行治疗,比较两组患者血糖、血压控制水平。结果:观察组患者治疗后舒张压水平为(85.4±6.2)mmHg,患者收缩压水平为(132.5±6.8)mmHg,与对照组比较存在明显差异,P<0.05。观察组患者空腹血糖水平为(5.1±0.7)mmol/L,餐后2h血糖水平为(6.5±1.4)mmol/L,比较存在明显差异,P>0.05。结论:贝拉普利能够更好的对患者血压、血糖水平进行控制,维持患者病情稳定。
OBJECTIVE: To investigate the therapeutic effect of berapril in hypertensive patients with diabetes mellitus. Methods: Seventy-eight patients with hypertension and diabetes mellitus were selected. All patients were admitted to hospital for treatment from October 2014 to January 2016. All patients were randomly divided into observation group and control group, 39 cases in each group and control group The patients in the observation group were treated with berapril simultaneously, and the levels of blood glucose and blood pressure were compared between the two groups. Results: The diastolic blood pressure in the observation group was (85.4 ± 6.2) mmHg after treatment, and the systolic blood pressure was (132.5 ± 6.8) mmHg in the observation group. There was a significant difference between the observation group and the control group (P <0.05). The fasting blood glucose level was (5.1 ± 0.7) mmol / L in the observation group and (6.5 ± 1.4) mmol / L 2 h after the meal, with significant difference (P> 0.05). Conclusion: Belaprost can better control the blood pressure and blood glucose level of patients and maintain the stable condition of patients.